[Cloning of prepronociceptin has led to the discovery of other biologically active peptides].
Among the opioid receptors family, the cloning of the mu, kappa and delta receptors was followed by that of another member, named ORL1 (Opiate Receptor Like 1). In spite of obvious homologies with the mu, kappa and delta receptors, ORL1 does not display a relevant affinity for the endogenous ligands of these former receptors (beta endorphin, enkephalins, dynorphin A...). This observation has prompted to search for an endogenous ligand of ORL1. A heptadecapeptide which fulfils this function, with a nanomolar affinity, has been found. It was named either nociceptin or orphanin FQ. It demonstrates, according either to the dose or to the route of administration, hyperalgesic, allodynic, antiopioidergic or even analgesic effects. It displays also many behavioural effects, modifying especially locomotion, exploratory behaviour, motivation, anxiety, memory, food intake. Nociceptin results from the cleavage of a large precursor protein, prepronociceptin (PPNOC). In this latter, nociceptin is flanked on its C-terminal region by another peptide which may be regarded either as a heptadecapeptide (NocII), or a bidecapeptide (NocIII) according to the inclusion or not of a fragment constituted by 3 arginine residues. Investigating the functions modulated by NocII, we observed that it stimulates locomotor activity of mice and shortens the forepaws licking latency in the hot plate test (55 degrees C); these effects are not shared by NocIII. The simultaneous administration of NocII and nociceptin resulted in animals put on the hot plate to the appearance of their respective effects, not modified by the presence of the other. A 41 amino acid peptide flanks nociceptin on its N-terminal region in PPNOC. It may be cleaved to generate a heptadecapeptide, named nocistatin on account of its antagonist effect on the hyperalgesia/allodynia induced by nociceptin. Thus, the discovery of ORL1 has led to that of nociceptin, that of its precursor PPNOC, and thereby to that of NocII/NocIII and nocistatin. The functions modulated by these peptides are being investigated whereas their receptors are yet unknown. These multiple targets allow to expect new strategies to modulate their functions.
Costentin
J
J
Unité de Neuropsychopharmacologie expérimentale, UPRESA 6036 CNRS, Faculté de Médecine et de Pharmacie de Rouen, Saint Etienne du Rouvray, France.
Florin
S
S
Suaudeau
C
C
Meunier
J C
JC
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003001:Cloning, Molecular; D006801:Humans; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D018847:Opioid Peptides / Q000235:genetics* / Q000494:pharmacology* / Q000502:physiology; D011498:Protein Precursors / Q000096:biosynthesis / Q000235:genetics; D011957:Receptors, Opioid / Q000502:physiology*; D000094942:Nociceptin Receptor; D000097629:Nociceptin
D018847:Opioid Peptides; D011498:Protein Precursors; D011957:Receptors, Opioid; D000094942:Nociceptin Receptor; D000097629:Nociceptin